ReviewJournal francais d'ophtalmologie2023
Acute macular neuroretinopathy and COVID-19 vaccination: Case report and literature review.
Review in Journal francais d'ophtalmologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- The characteristics of white dot syndromes following COVID-19 Vaccines: a systematic review.International ophthalmology · 2024Pooled it
- A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.European journal of medical research · 2023Pooled it
- Ultra-high-resolution imaging of acute macular neuroretinopathy: a case report.American journal of ophthalmology case reports · 2026Article
- Acute macular neuroretinopathy: is the name still appropriate?Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Acute Macular Neuroretinopathy in Association with Orbital Inflammation and Optic Perineuritis.Neuro-ophthalmology (Aeolus Press) · 2026Article
- Atypical presentation of acute macular neuroretinopathy: a case description.Quantitative imaging in medicine and surgery · 2025Article
- Article
- Acute macular neuroretinopathy following COVID-19 infection: Three case reports.World journal of clinical cases · 2024Article
- Multicenter and multimodal imaging study reveals rare fundus lesions in patients after SARS-CoV-2 infection.Scientific reports · 2024Article
- Acute Macular Neuroretinopathy after SARS-CoV-2 Infection: An Analysis of Clinical and Multimodal Imaging Characteristics.Diagnostics (Basel, Switzerland) · 2023Article
- Long-term follow-up of a young male who developed acute macular neuroretinopathy following COVID-19 vaccination.Clinical case reports · 2023Article
- Acute-Onset Retinal Conditions Mimicking Acute Optic Neuritis: Overview and Differential Diagnosis.Journal of clinical medicine · 2023Review
- Transient Increase in Patient Numbers with "Acute Macular Neuroretinopathy" Post SARS-CoV-2 Infection-Case Series During the First Surge of Infection in December 2022.Journal of inflammation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo review cases of acute macular neuroretinopathy (AMN) after COVID-19 vaccination and add a similar case to the literature.
methodsA thorough PubMed search was conducted, and data from studies describing AMN after COVID-19 vaccination were extracted, tabulated, pooled, and reviewed.
resultsWe present a case of AMN in a young woman 5 days after immunization with the BBIBP-CorV (Sinopharm) COVID-19 vaccine. Data from 21 cases were pooled and reviewed. The most frequent vaccines among the cases were recombinant ones (13/21), followed by mRNA-based (6/21) and inactivated vaccines (2/21). Only one patient (5%) was male. Seventeen over twenty-one (81%) were young women, ages 18-33. Most cases (14/21; 67%) reported recent/concurrent use of contraceptive medication. In 90% of cases (19/21), symptoms appeared within 8 days of vaccination. A confined wedge-/oval-shaped lesion morphology was more frequent than a diffuse, semilunar one. Resolution of symptoms took 4 to over 15 weeks.
conclusionAttention should be paid to the history of vaccination and contraceptive use in patients with sudden-onset visual symptoms. Optical coherence tomography is integral to the detection of AMN-related abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.